ideasIdea
Oncology pharmacists as protocol prescribers for supportive care and dose adjustments
Let specially trained cancer pharmacists prescribe anti-sickness drugs, growth-factor support and routine dose adjustments under protocols, freeing oncologists for decisions only they can make.
Oncology pharmacists already check every chemotherapy prescription; in several countries (UK, parts of Canada and the US) they hold independent or collaborative prescribing rights for supportive medicines and protocol dose modifications. Extending this model widely, with a defined competency framework, removes a large fraction of routine prescribing from oncologists' clinics and shortens chair waits caused by prescription queries.
Hypothesis
Units with pharmacist protocol prescribing will reduce oncologist time per chemotherapy cycle by at least 20% and reduce day-of-treatment prescription delays by half, with no increase in medication errors.
Rationale
Pharmacists are the profession with the deepest drug-dosing training; collaborative prescribing has shown equivalent safety in anticoagulation, diabetes, and HIV care.
What would test it
A twelve-month before-and-after study across five day units with time-motion measurement, delay logs, and an independent error audit.
Maturity
early clinical
Who has to act
regulator
Cost to try
Small (under $1M)
Years to first evidence
2
Bottlenecks it attacks
- Not enough oncologists, nurses, pathologists, physicists · The number of people with cancer is rising faster than the workforce trained to treat them.
- Fragmented care and guideline gaps · Patients fall between specialists, wait for referrals and often do not get the treatment guidelines say they should.